- Home
- BFST vs JANX Comparison
BFST vs JANX Comparison
Compare BFST & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | JANX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 847.1M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFST | JANX |
|---|---|---|
| Price | $27.98 | $14.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $32.75 | ★ $47.00 |
| AVG Volume (30 Days) | 141.8K | ★ 865.2K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | ★ 23.45 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $10,704,000.00 | $10,000,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $5.02 | N/A |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $22.56 | $12.12 |
| 52 Week High | $30.32 | $35.34 |
Technical Indicators
Market Signals| Indicator | BFST | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 51.12 |
| Support Level | $26.73 | $13.10 |
| Resistance Level | $28.74 | $14.57 |
| Average True Range (ATR) | 0.53 | 0.57 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 75.72 | 73.97 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.